Nothing Special   »   [go: up one dir, main page]

GT200500221A - Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan. - Google Patents

Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan.

Info

Publication number
GT200500221A
GT200500221A GT200500221A GT200500221A GT200500221A GT 200500221 A GT200500221 A GT 200500221A GT 200500221 A GT200500221 A GT 200500221A GT 200500221 A GT200500221 A GT 200500221A GT 200500221 A GT200500221 A GT 200500221A
Authority
GT
Guatemala
Prior art keywords
rna
inhibitors
dependents
treatments
compositions
Prior art date
Application number
GT200500221A
Other languages
English (en)
Inventor
Javier Gonzalez
Tanya Michelle Jewell
Hui Li
Angelica Linton
John Howard Tatlock
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of GT200500221A publication Critical patent/GT200500221A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS DE FORMULA (4) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES Y SOLVATOS, QUE SON ÚTILES COMO INHIBIDORES DE LA ENZIMA POLIMERASAS DEL VIRUS DE LA HEPATITIS C (HCV) Y TAMBIÉN SON ÚTILES PARA EL TRATAMIENTO DE INFECCIONES POR HCV EN MAMIFEROS INFECTADOS POR HCV. LA PRESENTE INVENCIÓN TAMBIÉN PROPORCIONA COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN COMPUESTOS DE FÓRMULA (4), SUS SALES FARMACÉUTICAMENTE ACEPTABLES Y SOLVATOS. ADEMÁS, LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS INTERMEDIOS Y MÉTODOS ÚTILES EN LA PREPARACIÓN DE COMPUESTOS DE FÓRMULA (4).
GT200500221A 2004-08-18 2005-08-16 Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan. GT200500221A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60261804P 2004-08-18 2004-08-18

Publications (1)

Publication Number Publication Date
GT200500221A true GT200500221A (es) 2006-06-21

Family

ID=35429645

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500221A GT200500221A (es) 2004-08-18 2005-08-16 Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan.

Country Status (43)

Country Link
US (3) US7151105B2 (es)
EP (1) EP1781662B1 (es)
JP (1) JP4372195B2 (es)
KR (1) KR100851178B1 (es)
CN (2) CN101538268B (es)
AP (1) AP2313A (es)
AR (1) AR050699A1 (es)
AT (1) ATE506364T1 (es)
AU (1) AU2005273619B2 (es)
BR (1) BRPI0514425A (es)
CA (1) CA2577525C (es)
CR (2) CR8935A (es)
CY (1) CY1111480T1 (es)
DE (1) DE602005027580D1 (es)
DK (1) DK1781662T3 (es)
EA (1) EA012605B1 (es)
EC (1) ECSP077264A (es)
ES (1) ES2361845T3 (es)
GE (2) GEP20115305B (es)
GT (1) GT200500221A (es)
HK (1) HK1109617A1 (es)
HN (1) HN2005000449A (es)
HR (1) HRP20110458T1 (es)
IL (2) IL180933A (es)
MA (1) MA28803B1 (es)
MX (1) MX2007001527A (es)
MY (1) MY146123A (es)
NI (1) NI200700043A (es)
NL (1) NL1029755C2 (es)
NO (1) NO20071274L (es)
NZ (1) NZ552874A (es)
PE (1) PE20060677A1 (es)
PL (1) PL1781662T3 (es)
PT (1) PT1781662E (es)
RS (1) RS51794B (es)
SI (1) SI1781662T1 (es)
SV (1) SV2007002202A (es)
TN (1) TNSN07066A1 (es)
TW (1) TWI376379B (es)
UA (1) UA88909C2 (es)
UY (1) UY29068A1 (es)
WO (1) WO2006018725A1 (es)
ZA (1) ZA200700779B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018725A1 (en) * 2004-08-18 2006-02-23 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
EP1928878A1 (en) * 2005-08-24 2008-06-11 Pfizer Inc. Methods for the preparation of hcv polymerase inhibitors
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
EP2008996A1 (en) * 2007-06-27 2008-12-31 Syngeta Participations AG Process for the production of pyrazoles
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びhcv感染の治療におけるその使用
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US8563717B2 (en) 2008-08-11 2013-10-22 Glaxosmithkline Llc Adenine derivatives
EA201100114A1 (ru) 2008-08-11 2011-10-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
KR20120106942A (ko) 2009-10-30 2012-09-27 베링거 인겔하임 인터내셔날 게엠베하 Bi201335, 인터페론 알파 및 리바비린을 포함하는 hcv 병용 치료요법을 위한 투여 용법
EP2325173A1 (de) 2009-11-19 2011-05-25 Bayer CropScience AG Verfahren zum Herstellen von 5-Fluor-1-alkyl-3-fluoralkyl-1H-pyrazol-4-carbonsäurechloriden
CN102753173A (zh) * 2009-12-18 2012-10-24 贝林格尔.英格海姆国际有限公司 Hcv组合疗法
EA021048B1 (ru) 2010-02-10 2015-03-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
JP5763179B2 (ja) * 2010-05-20 2015-08-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 1−アルキル−3−ジフルオロメチル−5−ヒドロキシピラゾール類の製造方法
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
FR2972452B1 (fr) 2011-03-09 2013-03-15 Rhodia Operations Procede de preparation du difluoroacetonitrile et de ses derives
CN104254523B (zh) 2012-05-14 2017-03-22 拜尔农作物科学股份公司 制备1‑烷基‑3‑氟烷基‑1h‑吡唑‑4‑羧酸氯的方法
WO2014081878A2 (en) 2012-11-21 2014-05-30 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival
DK2945933T3 (en) 2013-01-17 2017-01-23 Bayer Cropscience Ag METHOD OF PREPARING 5-FLUORO-1-METHYL-3-DIFLUORMETHYL-1H-PYRAZOL-4-CARBALDEHYDE
ES2656012T3 (es) 2013-02-06 2018-02-22 Bayer Cropscience Aktiengesellschaft Derivados de pirazol sustituidos con halógeno como pesticidas
AU2014375265B2 (en) 2014-01-03 2018-11-01 Elanco Animal Health Gmbh Novel pyrazolyl-heteroarylamides as pesticides
DK3097081T3 (da) 2014-01-24 2018-01-29 Bayer Cropscience Ag Fremgangsmåde til fremstilling af 1-alkyl-3-difluormethyl-5-fluor-1h-pyrazol-4-carbaldehyder og 1-alkyl-3-difluormethyl-5-fluor-1h-pyrazol-4-carboxylater
ES2655940T3 (es) 2014-02-20 2018-02-22 Glaxosmithkline Intellectual Property (No. 2) Limited Derivados de pirrolo[3,2-d]pirimidina como inductores de interferón humano
PT3152199T (pt) 2014-06-03 2018-11-26 Idorsia Pharmaceuticals Ltd Compostos de pirazol e a sua utilização como bloqueadores de canais de cálcio do tipo t
BE1023340B1 (fr) 2014-11-13 2017-02-08 Glaxosmithkline Biologicals S.A. Composes
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingの調節因子としての環状プリンジヌクレオチド
CR20200045A (es) 2016-04-07 2020-03-11 Glaxosmithkline Ip Dev Ltd AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472)
SG11201808708RA (en) 2016-04-07 2018-11-29 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
WO2018033455A1 (de) 2016-08-15 2018-02-22 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
MA49114A (fr) 2016-12-16 2020-03-25 Idorsia Pharmaceuticals Ltd Combinaison pharmaceutique comprenant un bloqueur de canal calcique de type t
US10899695B2 (en) 2017-02-06 2021-01-26 Idorsia Pharmaceuticals Ltd Process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
MX2020003604A (es) 2017-10-04 2020-07-28 Bayer Ag Derivados heterociclicos como pesticidas.
JP7291130B2 (ja) 2017-10-05 2023-06-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド インターフェロン遺伝子の刺激物質(sting)の調節物質
JP2020536106A (ja) 2017-10-05 2020-12-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Hivの処置に有用なインターフェロン遺伝子の刺激物質(sting)の調節物質
EP3765466B1 (de) 2018-03-12 2022-05-25 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
US20210169080A1 (en) 2018-04-20 2021-06-10 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
EP3969438A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
US20220251079A1 (en) 2019-05-16 2022-08-11 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CN112194620B (zh) * 2020-12-04 2021-02-26 苏州开元民生科技股份有限公司 一种2-乙基-4-氰基吡啶的制备方法
CN113563167B (zh) * 2021-07-16 2023-09-08 南通华祥医药科技有限公司 一种2-甲基-1-四氢萘酮的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786063A (en) 1971-05-24 1974-01-15 Universal Oil Prod Co Thiazolethiosulfonates
DE2155360C3 (de) * 1971-11-08 1980-04-03 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von Acylbernsteinsäuredialkylestern
CA1140049A (en) 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
US4326058A (en) 1979-02-05 1982-04-20 Sumitomo Chemical Company, Limited Organo-phosphoric esters and their production and use
US4489077A (en) 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US5846964A (en) 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
US5504104A (en) 1993-11-19 1996-04-02 Warner-Lambert Company Tricyclic pyrone derivatives as protease inhibitors and antiviral agents
US5808062A (en) 1993-11-19 1998-09-15 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
US5840751A (en) 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
RU2160733C2 (ru) 1993-11-19 2000-12-20 Парк, Дэвис энд Компани Производные пирона и их фармацевтически приемлемые соли, промежуточные соединения для их получения, фармацевтическая композиция с антивирусной и антибактериальной активностью на их основе, способ лечения вызванных ретровирусом инфекции или заболевания
WO1995014012A1 (en) 1993-11-19 1995-05-26 Parke, Davis & Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US5834506A (en) * 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
AU773567B2 (en) 1998-09-11 2004-05-27 Warner-Lambert Company HIV protease inhibitors
US6512006B1 (en) 1999-12-09 2003-01-28 Warner-Lambert Company HIV protease inhibitors
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
DOP2003000641A (es) * 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2006018725A1 (en) * 2004-08-18 2006-02-23 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same

Also Published As

Publication number Publication date
JP4372195B2 (ja) 2009-11-25
CR20110153A (es) 2011-04-26
AP2007003918A0 (en) 2007-02-28
CA2577525A1 (en) 2006-02-23
CN101538268A (zh) 2009-09-23
HN2005000449A (es) 2009-10-30
JP2008509984A (ja) 2008-04-03
KR100851178B1 (ko) 2008-08-08
EA012605B1 (ru) 2009-10-30
HRP20110458T1 (hr) 2011-07-31
NZ552874A (en) 2010-04-30
EP1781662A1 (en) 2007-05-09
CA2577525C (en) 2010-03-30
US7622605B2 (en) 2009-11-24
PT1781662E (pt) 2011-07-01
DK1781662T3 (da) 2011-06-27
DE602005027580D1 (de) 2011-06-01
EP1781662B1 (en) 2011-04-20
MA28803B1 (fr) 2007-08-01
GEP20115305B (en) 2011-10-10
SV2007002202A (es) 2007-03-20
CY1111480T1 (el) 2015-08-05
SI1781662T1 (sl) 2011-07-29
KR20070044057A (ko) 2007-04-26
TNSN07066A1 (fr) 2008-06-02
US20070015764A1 (en) 2007-01-18
US8268835B2 (en) 2012-09-18
CR8935A (es) 2007-07-24
AP2313A (en) 2011-10-31
US7151105B2 (en) 2006-12-19
RS51794B (en) 2011-12-31
US20090281122A1 (en) 2009-11-12
ES2361845T3 (es) 2011-06-22
IL192919A0 (en) 2009-02-11
MX2007001527A (es) 2007-03-27
NL1029755A1 (nl) 2006-02-21
NO20071274L (no) 2007-05-14
WO2006018725A1 (en) 2006-02-23
TWI376379B (en) 2012-11-11
ATE506364T1 (de) 2011-05-15
BRPI0514425A (pt) 2008-06-10
ECSP077264A (es) 2007-04-26
AU2005273619A1 (en) 2006-02-23
GEP20094751B (en) 2009-08-10
PE20060677A1 (es) 2006-08-11
PL1781662T3 (pl) 2011-08-31
CN101538268B (zh) 2011-07-27
US20060122399A1 (en) 2006-06-08
NI200700043A (es) 2008-01-02
UY29068A1 (es) 2006-03-31
IL180933A (en) 2011-08-31
HK1109617A1 (en) 2008-06-13
MY146123A (en) 2012-06-29
UA88909C2 (ru) 2009-12-10
EA200700338A1 (ru) 2007-08-31
TW200612898A (en) 2006-05-01
AR050699A1 (es) 2006-11-15
NL1029755C2 (nl) 2006-10-18
IL180933A0 (en) 2007-07-04
CN101006092B (zh) 2013-04-17
AU2005273619B2 (en) 2009-05-28
CN101006092A (zh) 2007-07-25
ZA200700779B (en) 2008-11-26

Similar Documents

Publication Publication Date Title
GT200500221A (es) Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan.
UY28192A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan.
CU20100062A7 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
NI201300107A (es) Derivados de nucleósidos 2' - sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales.
MX2022016405A (es) Análogos de nucleósido de 1¿-ciano y usos de estos.
ECSP10010210A (es) Compuestos nucleósidos antivirales
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
UY28084A1 (es) Derivados antivirales de nucleosidos
DOP2012000243A (es) Compuestos de sililo tricíclicos fusionados y uso de los mismos en la fabricación de medicamentos útiles en el tratamiento de enfermedades virales
ECSP109934A (es) Compuesto - 946
PE20210668A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
UY27333A1 (es) Nucleótidos 4` sustituidos
DK2203430T3 (da) N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
EA200901241A1 (ru) Соединения для лечения гепатита с
BR112013020042A2 (pt) inibidores de vírus da hepatite c
BRPI0815920A2 (pt) Composto, composição farmacêutica, e, uso do composto.
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
BR112014013972A2 (pt) inibidores de hcv nssa
PA8573401A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan
BR112014015582A8 (pt) compostos antivirais
PA8590801A1 (es) Derivados de nucleosido antivirales
CU23533A3 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan
DOP2005000165A (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan